MedImmune Wins Supreme Court Decision vs. Genentech
MedImmune, Inc. issued the following statement regarding the U.S. Supreme Court decision in MedImmune, Inc. vs. Genentech, Inc. et al.:
By granting MedImmune’s appeal, the U.S. Supreme Court has brought further clarity to the patent litigation process — specifically, the use of declaratory judgments by licensees of questionable patents. The Court’s decision means MedImmune is free to pursue its complaint regarding non-infringement, invalidity, and unenforceability of the Cabilly II patent. We intend to do so vigorously and are confident that our position will prevail. We appreciate the support MedImmune’s position on this issue received in the amicus briefs filed by various parties, including the U.S. Solicitor General; the General Counsel of the U.S. Patent & Trademark Office; the Generic Pharmaceuticals Association; three intellectual property professors; the Natural Resources Defense Counsel, and legal counsel for Medtronic, Inc.
